After hours

Moderna, Inc.

MRNA · Nasdaq

Analyst Consensus

Hold

21 analysts

$133

Current

—

Low

$48

Average

—

High

Average target implies -64.00% versus the current price.

Analyst Ratings Synthesis

Published consensus is inconsistent rather than a single usable figure: one StockAnalysis snippet cites 23 S&P Global analysts at Hold with an $89.33 average, while TipRanks cites 15 analysts, a $40-$170 range and an average implying 52.79% upside; AnaChart reports an $18-$77 range and a $40.08 average. BofA’s Alex Stranahan is the most bullish identifiable actor, moving to Neutral with a $170 target from $40; no named analyst is tied to the $18 low. The supplied record shows no action dated during August 17-21, so revision direction is unknown. The spread reflects different analyst datasets, but no fundamental rationale is supplied.

Rating Actions

No individual rating actions have been captured for MRNAyet. Consensus figures above come from Nasdaq's aggregate feed.

Rating actions are extracted from published reporting. Each row links to its source.

Research Reports

Links to freely available third-party research. Outlook labels are our classification of each article's stance, not a rating of our own.

Covering Firms

ARGUS RESEARCH

B OF A GLBL RES

BARCLAYS CAPITA

BROOKLINE CAP M

CANACCORD GENUI

CHARDAN CAPITAL

DEUTSCHE BK SEC

GOLDMAN SACHS

GUGGENHEIM SEC.

HSBC GLOBAL RES

JEFFERIES & CO.

JP MORGAN SECUR

LEERINK PARTNRS

MORGAN STANLEY

OPPENHEIMER HLD

PIPER SANDLER

RBC CAPITAL

TD COWEN

UBS

WILLIAM BLAIR

ZACKS RESEARCH

Symbol: MRNA
Type: Stock
Sector: Health Care
Industry: Biotechnology: Biological Products (No Diagnostic Substances)
Country: North America
Exchange: Nasdaq

Intismeran autogene (intismeran; V940 or mRNA-4157) is a novel, potential first-in-class investigational messenger RNA (mRNA)-based individualized neoantigen therapy (INT) jointly developed by Merck and Moderna. Intismeran is designed and produced using a patient's tumor sample to identify the unique mutational signature, or 'fingerprint,' of their cancer and generate an anti-tumor immune response. Each therapy consists of a synthetic mRNA coding for up to 34 neoantigens and is tailored to the unique biology of an individual patient's tumor. Upon administration, the RNA-encoded neoantigen sequences are translated in the body and presented to the immune system, a key step in generating specific T-cell responses against cancer cells. Individualized neoantigen therapies are designed to train and activate an anti-tumor immune response based on the unique mutational signature of a patient's tumor.

Key Issues

Bullish view

Net loss narrowed to $2.8 billion in FY2025 from $3.6 billion in FY2024, suggesting progress even as revenue declined.

Bearish view

Moderna remained deeply unprofitable in FY2025, while revenue fell to $1.9 billion from $3.2 billion, so the improvement may not represent a durable recovery.

Analyst Consensus

See all

Hold

21 analysts

$133

Current

—

Low

$48

Average

—

High

Average target implies -64.00% versus the current price.

Earnings History

BeatMissNo estimate

Moderna, Inc.

Analyst Consensus

Analyst Ratings Synthesis

Rating Actions

Research Reports

Covering Firms

Peers